Literature DB >> 10570291

Differential impact of substitution of amino acids 9-13 and 91-101 of human CD14 on soluble CD14-dependent activation of cells by lipopolysaccharide.

F Stelter1, H Loppnow, R Menzel, U Grunwald, M Bernheiden, R S Jack, A J Ulmer, C Schütt.   

Abstract

The soluble form of the endotoxin receptor CD14 is required for the LPS-induced activation of cells lacking membrane-bound CD14. It has been shown that a deletion mutant of human CD14 consisting of the N-terminal 152 amino acids has the capacity to mediate the stimulation of different cell types by LPS. To identify the structural domains of the molecule related to this functional property, we screened a set of alanine substitution mutants using CD14-negative U373 astrocytoma cells. We show that 3 of 18 soluble mutants of human CD14 failed to mediate the LPS-induced IL-6 production in U373 cells. These mutants were located in two regions of the molecule (aa 9-13 and 91-101) that are not essential for LPS binding. In addition, the mutants had a reduced capacity to mediate LPS-stimulated IL-6 production in human vascular endothelial and SMC. In contrast, the potential of sCD14(91-94,96)A, and sCD14(97-101)A to signal LPS-induced activation of human PBMC was not significantly reduced. These results show that the regions 9-13 and 91-101 are involved in the sCD14-dependent stimulation of cells by LPS but that the mechanisms by which different cell types are activated may not be identical.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570291

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

2.  N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.

Authors:  Dongxu Liu; Cort C Cramer; Jennifer Scafidi; Alvin E Davis
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex.

Authors:  S Baveye; E Elass; D G Fernig; C Blanquart; J Mazurier; D Legrand
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 4.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

Review 5.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

6.  N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice.

Authors:  Dongxu Liu; Xiaogang Gu; Jennifer Scafidi; Alvin E Davis
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

7.  Human proteinase 3 can inhibits LPS-mediated TNF-alpha production through CD14 degradation: lack of influence of antineutrophil cytoplasmic antibodies.

Authors:  B A Yard; A-I Wille; M Haak; F J van der Woude
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

8.  The N-terminus of CD14 acts to bind apoptotic cells and confers rapid-tethering capabilities on non-myeloid cells.

Authors:  Leanne Thomas; Anne Bielemeier; Peter A Lambert; Richard P Darveau; Lindsay J Marshall; Andrew Devitt
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.